Case Reports
30 July 2025
Early Access
https://doi.org/10.4081/dr.2025.10379

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Psoriasis, risankizumab, erythrodermic psoriasis, safety, efficacy
21
Views
10
Downloads

Authors

Andrea D'Arino
https://orcid.org/0000-0002-0669-1442
Oncologic and Preventive Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Maria Concetta Fargnoli
https://orcid.org/0000-0002-7249-2556
Scientific Direction, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Pasquale Frascione
https://orcid.org/0000-0002-5592-8485
Oncologic and Preventive Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Chiara Assorgi
Dermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, Rome, Italy.
Annunziata Dattola
https://orcid.org/0000-0001-9504-5882
Dermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, Rome, Italy.
Viviana Lora
Clinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Matteo Megna
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy.
Flavia Pigliacelli
Clinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Emanuele Vagnozzi
Dermatology Unit, Department of Clinical Internal, Anesthesiological, and Cardiovascular Science, La Sapienza University, Rome, Italy.
Diego Orsini
diego.orsini@ifo.it
Clinical Dermatology Unit, IRCCS San Gallicano Dermatological Institute, Rome, Italy.

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several small studies and case reports that provide evidence for the potential use of biologic therapies in the treatment of erythrodermic psoriasis. This case series suggests that risankizumab may represent an effective and sustainable treatment option for patients with a history of EP.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015;136:116-124.e7. DOI: https://doi.org/10.1016/j.jaci.2015.01.018
2. Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996;34:911-4. DOI: https://doi.org/10.1016/S0190-9622(96)90078-X
3. Narcisi A, Bernardini N, Orsini D, et al. Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Postepy Dermatol Alergol 2020;37:428-34. DOI: https://doi.org/10.5114/ada.2020.96910
4. Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther 2021;34:e14825.
5. Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther 2021;34:e14825. DOI: https://doi.org/10.1111/dth.14825
6. Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: A systematic review. J Am Acad Dermatol 2020;83:151-8. DOI: https://doi.org/10.1016/j.jaad.2020.03.073
7. Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther 2018;12:3879-83. DOI: https://doi.org/10.2147/DDDT.S167149
8. Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol 2024;38:e113-6. DOI: https://doi.org/10.1111/jdv.19464
9. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother 2020;54:380-7. DOI: https://doi.org/10.1177/1060028019885836
10. Alajlan A, Madani A, Qadoumi TA, et al. Erythrodermic Psoriasis Managed with Risankizumab. Case Rep Dermatol 2022;14:219-24. DOI: https://doi.org/10.1159/000525774
11. Hsu CC, Hsieh CY, Tsai TF. Clinical Experience of Risankizumab in Patients With a History of Erythrodermic Psoriasis. Exp Dermatol 2025;34:e70080. DOI: https://doi.org/10.1111/exd.70080
12. Orsini D, Assorgi C, Bonifati C, et al. Effectiveness and safety of risankizumab in very severe plaque psoriasis: a real-life retrospective study (VESPA-Study). J Dermatol Treat 2024;35:2358150. DOI: https://doi.org/10.1080/09546634.2024.2358150

How to Cite



Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10379
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.